The committee will discuss postmarketing requirement (PMR) 3033-11, issued to application holders of new drug applications (NDAs) for extended-release and long-acting (ER/LA) opioid analgesics to evaluate long-term efficacy of opioid analgesics and the risk of opioid-induced hyperalgesia. The discussion will focus on a clinical trial designed to address these objectives.
Link to Meeting Information and Materials: [ Ссылка ]

свернуть